Clinical Trial Update: A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing 24-week versus 48-week courses of peginterferon plus ribavirin for genotype 1 hepatitis C patients with IL28B CC polymorphi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Chronic Hepatitis C | Phase 3 | Status: UNKNOWN